目的探讨国产胸腺肽α1(基泰)辅助抗感染治疗的临床疗效。方法120例肝硬化腹水并自发性腹膜炎患者,随机分为治疗组和对照组,两组在使用相同抗菌素的情况下,治疗组加用胸腺肽α1,治疗两周后,统计分析临床疗效。结果治疗组总有效率为87.1%,对照组为56.0%。两组差异有统计学意义(P<0.05)。结论国产胸腺肽α1辅助治疗肝硬化腹水并自发性腹膜炎的疗效显著。 Objective To investigate the clinical efficacy of domestic thymosin α1 (Ketai) adjuvant anti-infective therapy. Methods 120 patients with cirrhosis and spontaneous peritonitis were randomly divided into treatment group and control group. The two groups were given thymosin α1 with the same antibiotics. After two weeks of treatment, the clinical efficacy was statistically analyzed. Results The total effective rate was 87.1% in the treatment group and 56.0% in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion Domestic thymosin α1 adjuvant treatment of cirrhosis and spontaneous peritonitis have a significant effect.